Moutos D, Smith S, Zacur H
Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Contraception. 1995 Aug;52(2):105-9. doi: 10.1016/s0010-7824(95)00137-9.
The effects of different monophasic combinations of ethinyl estradiol and norethindrone on FSH, LH, sex hormone binding globulin, total testosterone, androstenedione, and dehydroepiandrosterone sulfate levels in non-obese, non-hirsute women were compared. Retrospective analysis of frozen serum from a prospective randomized trial in which women received one of three oral contraceptive pills containing ethinyl estradiol 50 micrograms/norethindrone 1 mg, ethinyl estradiol 35 micrograms/norethindrone 1 mg or ethinyl estradiol 35 g/norethindrone 0.5 mg for nine cycles was conducted. Blood samples were obtained prior to treatment and during the third, sixth and ninth pill cycles. Ethinyl estradiol 50 micrograms/norethindrone 1 mg and ethinyl estradiol 35 micrograms/norethindrone 1 mg suppressed FSH, LH, and total testosterone and increased sex hormone binding globulin to a similar degree. Ethinyl estradiol 35 micrograms/norethindrone 0.5 mg resulted in less suppression of FSH, LH, and total testosterone, but greater elevation of sex hormone binding globulin. Dehydroepiandrosterone sulfate was suppressed to a similar degree with ethinyl estradiol 35 micrograms/norethindrone 1 mg and ethinyl estradiol 35 micrograms/norethindrone 0.5 mg, but ethinyl estradiol 50 micrograms/norethindrone 1 mg resulted in the least suppression of dehydroepiandrosterone sulfate. Ethinyl estradiol 35 micrograms/norethindrone 1 mg caused greater suppression of androstenedione than did the other two oral contraceptives. Oral contraceptive-induced changes in gonadotropins, androgens, and sex hormone binding globulin can be predicted by considering the relative amounts of estrogen and progestin in the pill. When combined with 1 mg of norethindrone, 50 micrograms of ethinyl estradiol did not result in greater suppression of FSH, LH, or total testosterone or in greater elevation of sex hormone binding globulin than did 35 micrograms of ethinyl estradiol.
比较了炔雌醇与炔诺酮不同单相组合对非肥胖、无多毛症女性促卵泡生成素（FSH）、促黄体生成素（LH）、性激素结合球蛋白、总睾酮、雄烯二酮和硫酸脱氢表雄酮水平的影响。对一项前瞻性随机试验中冷冻血清进行回顾性分析，该试验中女性服用三种口服避孕药之一，分别含50微克炔雌醇/1毫克炔诺酮、35微克炔雌醇/1毫克炔诺酮或35微克炔雌醇/0.5毫克炔诺酮，为期九个周期。在治疗前以及第三个、第六个和第九个服药周期采集血样。50微克炔雌醇/1毫克炔诺酮和35微克炔雌醇/1毫克炔诺酮对FSH、LH和总睾酮的抑制作用以及对性激素结合球蛋白的升高作用程度相似。35微克炔雌醇/0.5毫克炔诺酮对FSH、LH和总睾酮的抑制作用较小，但对性激素结合球蛋白的升高作用较大。35微克炔雌醇/1毫克炔诺酮和35微克炔雌醇/0.5毫克炔诺酮对硫酸脱氢表雄酮的抑制程度相似，但50微克炔雌醇/1毫克炔诺酮对硫酸脱氢表雄酮的抑制作用最小。35微克炔雌醇/1毫克炔诺酮对雄烯二酮的抑制作用比其他两种口服避孕药更强。通过考虑避孕药中雌激素和孕激素的相对含量，可以预测口服避孕药引起的促性腺激素、雄激素和性激素结合球蛋白的变化。当与1毫克炔诺酮合用时，50微克炔雌醇对FSH LH或总睾酮的抑制作用以及对性激素结合球蛋白的升高作用并不比35微克炔雌醇更强。
